Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer

Immunology

Volumn 133, Issue 1, 2011, Pages 94-104

  Al Omar, Suliman Y ^a   Marshall, Ernie ^b   Middleton, Derek ^a,c   Christmas, Stephen E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cytotoxicity; Interferon ; Killer immunoglobulin like receptors; Lung cancer; Natural killer cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PERFORIN; PERFORIN A; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL SEPARATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LUNG NEOPLASMS; RECEPTORS, KIR; RECEPTORS, KIR2DL3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953300281     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03415.x     Document Type: Article

References (45)

1. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9.
2. Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003; 3:304-16.
3. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996; 4:77-85.
4. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998; 391:703-7.
5. Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol 2005; 35:10-5.
6. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 1991; 349:329-31.
7. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83:355-67.
8. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009; 6:224-32.
9. Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev Vaccines 2010; 9:323-35.
10. Yang Q, Goding SR, Hokland ME, Basse PH. Antitumor activity of NK cells. Immunol Res 2006; 36:13-25.
11. Sodeur S, Ullrich S, Gustke H, Zangemeister-Wittke U, Schumacher U. Increased numbers of spontaneous SCLC metastasis in absence of NK cells after subcutaneous inoculation of different SCLC cell lines into pfp/rag2 double knock out mice. Cancer Lett 2009; 282:146-51.
12. Ferson M, Edwards A, Lind A, Milton GW, Hersey P. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 1979; 23:603-9.
13. Lu LM, Zavitz CC, Chen B, Kianpour S, Wan Y, Stämpfli MR. Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol 2007; 178:936-43.
14. - cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-75.
15. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007; 149:1-8.
16. Le Maux Chansac B, Moretta A, Vergnon I et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005; 175:5790-8.
17. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, Salageanu A. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004; 53:1146-52.
18. Ciszak L, Kosmaczewska A, Werynska B, Szteblich A, Jankowska R, Frydecka I. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep 2009; 21:173-84.
19. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2006; 55:891-9.
20. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010; 71:976-81.
21. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5:201-14.
22. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R, Vilches C, Parham P. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001; 166:2992-3001.
23. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009; 114:3422-30.
24. Le Garff-Tavernier M, Béziat V, Decocq J et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 2010; 9:527-35.
25. Lutz CT, Moore MB, Bradley S, Shelton BJ, Lutgendorf SK. Reciprocal age related change in natural killer cell receptors for MHC class I. Mech Ageing Dev 2005; 126:722-31.
26. Mariani E, Monaco MC, Cattini L, Sinoppi M, Facchini A. Distribution and lytic activity of NK cell subsets in the elderly. Mech Ageing Dev 1994; 76:177-87.
27. Hayhoe RP, Henson SM, Akbar AN, Palmer DB. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. Hum Immunol 2010; 71:676-81.
28. Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000; 18:1613-20.
29. Mocchegiani E, Malavolta M. NK and NKT cell functions in immunosenescence. Aging Cell 2004; 3:177-84.
30. Rukavina D, Laskarin G, Rubesa G et al. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood 1998; 92:2410-20.
31. Mocchegiani E, Giacconi R, Cipriano C, Malavolta M. NK and NKT cells in aging and longevity: role of zinc and metallothioneins. J Clin Immunol 2009; 29:416-25.
32. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006; 214:155-60.
33. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-45.
34. Jonsson AH, Yokoyama WM. Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009; 101:27-79.
35. Luque I, Solana R, Galiani MD, González R, García F, López de Castro JA, Peña J. Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones. Eur J Immunol 1996; 26:1974-7.
36. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994; 180:1235-42.
37. + NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009; 83:6798-805.
38. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990; 172:1589-98.
39. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001; 167:3129-38.
40. Chrul S, Polakowska E, Szadkowska A, Bodalski J. Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells. Mediators Inflamm 2006; 2006:46957.
41. + NK cells. Biomarkers 2009; 14:258-70.
42. Ling P, Gately MK, Gubler U et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995; 154:116-27.
43. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008; 59:32-40.
44. Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M, Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35:23-8.
45. Iliopoulou EG, Kountourakis P, Karamouzis MV et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59:1781-9.